Sunday 18 October 2026
Export CTNM’s income statement to Excel — free account
Contineum Therapeutics, Inc.
CTNM Healthcare Biotechnology
Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million. In the quarter to June 2026, EPS grew 35.5% and free cash flow grew 26.7%, each against the same quarter a year earlier.
7.02
0.88
−11.14%
Follow CTNM
Contineum Therapeutics, Inc. (CTNM) P/E ratio
Contineum Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.5× (June 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 1.8× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 1.8× | — |
Against its own ten years
Low 0.0×
High 2.5×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SRZN Surrozen, Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| BNTC Benitec Biopharma Limited compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| ARCT Arcturus Therapeutics Holdings Inc. compare | n/m |
| AGEN Agenus Inc. compare | 2.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)